Interleukin-33 exacerbates collagen-induced arthritis

Rong MU,Hui-rong JIANG,Yu-bin LI,B Iain,Zhan-guo LI
DOI: https://doi.org/10.3760/cma.j.issn.1007-7480.2010.03.007
2010-01-01
Abstract:Objective To explore the role of a new cytokine interleukin (IL)-33 in collagen induced arthritis (CIA). Methods The murine model of CIA was employed. DBA/1 mice were immunized with C Ⅱ/CFA and challenged with the same dose of C Ⅱ in PBS on day 21. The mice were injected I.p daily with IL-33 or PBS for 5 clays from day 21. Lymphonodes were removed on day 28 after primary immunization and cultured. The concentrations of all eytokines of the supernatants were determined by ELISA or an 20-plex-mouse cyto-kine assay according to the manufacturer's instructions. Serum anti-C Ⅱ antibody and mice paw histology were. Also assessed. Two independent samples t test, chi-square test were used for statistical analysis. Results DBA/1 mice receiving IL-33 injection exhibited an exacerbated CIA both in terms of clinical evaluation and histological parameters. IL-17, IFN-γ, TNF-α, IL-5, IL-12, GM-CSF, MCP-1 and IP-10 productions were also elevated in IL-33 group (P<0.05). Similarly, mice in the IL-33 injection group had higher levels of anti-collagen antibodies compared with those of the controls. The concentrations of C Ⅱ-specific IgG2a were [(1.96±0.16) vs (1.24±sO.33) mg/L] (P<0.05), while IgG1 anti-C Ⅱ antibodies were [ (1.1±0.4) vs (1.7±0.4) mg/L] (P<0.05). Conclusion IL-33 is a critical pro-inflammatory cytokine for inflamm-atory joint disease. Thus this novel IL-1 supeffamily member represents a novel therapeutic target for rheumatoid arthritis ( RA ).
What problem does this paper attempt to address?